Latest

Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ The Pharmacist's Role: How Community Pharmacies in Ireland and the UK Are Adapting as Patients Bypass High-Street Stores for Direct Delivery ◆ GLP-1 Therapeutics and Clinical Research Updates: Brain Reward Mapping, Oral Small Molecules, and Triple-Agonist Horizons ◆ Rinn Pharma & Biopharma Joins NordicPharmaTrain Network to Accelerate European Research & Advanced Manufacturing ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ The Pharmacist's Role: How Community Pharmacies in Ireland and the UK Are Adapting as Patients Bypass High-Street Stores for Direct Delivery ◆ GLP-1 Therapeutics and Clinical Research Updates: Brain Reward Mapping, Oral Small Molecules, and Triple-Agonist Horizons ◆ Rinn Pharma & Biopharma Joins NordicPharmaTrain Network to Accelerate European Research & Advanced Manufacturing ◆

Search Results

Found 2 results for "cost-control" across articles, medicines, trials, companies and the glossary

The Cost-Governed Enterprise: A Financial Governance Playbook for AI in Irish Life Sciences

The Cost-Governed Enterprise: A Financial Governance Playbook for AI in Irish Life Sciences

MIT research found that 95% of enterprise generative AI pilots show no measurable P&L impact, despite up to €36.8bn of global investment. The failure is not the technology, it is governance: cost is billed and legible, return is diffuse and uninstrumented. A seven-band cost taxonomy, eight load-bearing equations and the make-versus-rent crossover that Irish life sciences boards need to close the gap.

The €8.5 Billion Defense: Dutch Innovative Pharma Fights Back Against Cost-Control Policies

The €8.5 Billion Defense: Dutch Innovative Pharma Fights Back Against Cost-Control Policies

The Dutch Association for Innovative Medicines (VIG) releases a detailed report highlighting the sector\'s €8.5 billion gross added value, warning that cost-containment measures threaten patient access, clinical trials, and Europe\'s biopharma sovereignty.